Zacks Research Analysts Increase Earnings Estimates for BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Zacks Research increased their Q2 2026 EPS estimates for shares of BioMarin Pharmaceutical in a report released on Wednesday, March 12th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $1.00 per share for the quarter, up from their prior estimate of $0.86. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s FY2027 earnings at $4.78 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The company had revenue of $747.31 million for the quarter, compared to the consensus estimate of $711.05 million.

A number of other analysts also recently commented on the stock. Wedbush restated an “outperform” rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Bank of America boosted their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Scotiabank boosted their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a “sector perform” rating in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $90.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Finally, UBS Group boosted their target price on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

BioMarin Pharmaceutical Stock Down 1.6 %

BMRN stock opened at $69.44 on Friday. BioMarin Pharmaceutical has a 52 week low of $60.63 and a 52 week high of $94.85. The company has a market capitalization of $13.25 billion, a price-to-earnings ratio of 31.56, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. The firm’s 50-day moving average is $66.22 and its two-hundred day moving average is $68.96. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BMRN. Janney Montgomery Scott LLC grew its position in BioMarin Pharmaceutical by 102.1% during the third quarter. Janney Montgomery Scott LLC now owns 11,700 shares of the biotechnology company’s stock valued at $822,000 after purchasing an additional 5,911 shares in the last quarter. Covestor Ltd grew its position in BioMarin Pharmaceutical by 336.4% during the third quarter. Covestor Ltd now owns 1,030 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 794 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in BioMarin Pharmaceutical by 20.6% during the third quarter. Crossmark Global Holdings Inc. now owns 13,322 shares of the biotechnology company’s stock valued at $937,000 after purchasing an additional 2,277 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in BioMarin Pharmaceutical during the third quarter valued at approximately $710,000. Finally, OVERSEA CHINESE BANKING Corp Ltd purchased a new position in BioMarin Pharmaceutical during the third quarter valued at approximately $246,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 1,344 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the transaction, the chief accounting officer now directly owns 13,105 shares of the company’s stock, valued at approximately $896,119.90. The trade was a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.85% of the stock is currently owned by insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.